Glass House Brands (GLAS) EBITDA (2020 - 2026)

Glass House Brands (GLAS) posted quarterly EBITDA of -$14.4 million for Q1 2026, down 13.13% quarter-over-quarter from -$12.7 million in Q4 2025.

Glass House Brands (GLAS) EBITDA (2020 - 2026) Analysis & Trends

Glass House Brands (GLAS) has reported EBITDA for 7 consecutive years, with -$14.4 million the latest figure, recorded in Q1 2026.

In Q1 2026, EBITDA changed N/A year-over-year to -$14.4 million; the TTM figure through Mar 2026 stood at -$27.8 million (changed N/A YoY), while the FY2025 annual figure was -$16.5 million, down 388.18% from the prior year.
EBITDA retreated to -$14.4 million in Q1 2026 per GLAS's latest filing, from -$12.7 million in the prior quarter.
Across five years, EBITDA topped out at $10.6 million in Q2 2025 and bottomed at -$14.4 million in Q1 2026.
Historically, EBITDA has averaged $900288.4 across 5 years, with a median of $3.0 million in 2022.
Annual changes were most pronounced in 2022 — EBITDA surged 348.81% — and 2023, when it plunged 92.62%.
Glass House Brands' EBITDA stood at $2.6 million in 2022, then soared by 45.28% to $3.8 million in 2023, then soared by 33.66% to $5.0 million in 2024, then sank by 351.52% to -$12.7 million in 2025, then decreased by 13.13% to -$14.4 million in 2026.
Business Quant data shows GLAS's EBITDA at -$14.4 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.4 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.42 Bn	39.76 Bn	2.15 Bn	-231.00 Mn
3	Zoetis	31.86 Bn	30.18 Bn	1.05 Bn	837.00 Mn
4	Takeda Pharmaceutical	28.77 Bn	22.98 Bn	5.10 Bn	1.26 Bn
5	United Therapeutics	22.29 Bn	19.63 Bn	683.80 Mn	330.80 Mn
6	Viatris	18.78 Bn	17.89 Bn	1.46 Bn	6.30 Mn
7	Neurocrine Biosciences	15.66 Bn	15.27 Bn	935.80 Mn	151.50 Mn
8	Elanco Animal Health	11.91 Bn	11.38 Bn	798.00 Mn	248.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	Glass House Brands	828.45 Mn	809.90 Mn	15.77 Mn	-3.00 Mn

Download Data